ClinicalTrials.gg
CompletedNCT03085836Updated Jan 30, 2019Results posted

A Pharmacokinetic Study of TAK-438 in Healthy Adult Chinese Participants

A Phase 1 interventional study of TAK-438 in Healthy Participants, sponsored by Takeda. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-01-30.

Sponsored by Takeda · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
33
Allocation
Non-randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

The purpose of this study is to determine the pharmacokinetics (PK) of TAK-438 in healthy adult Chinese participants after both single and multiple dose administration.

Read the detailed description

The drug being tested in this study is called TAK-438. TAK-438 is being tested in healthy participants in order to evaluate the PK of single and multiple oral dose.

The study will enroll approximately 36 healthy participants. Participants will be assigned to one of the three treatment groups:

  • TAK-438 10 mg tablet once daily
  • TAK-438 20 mg tablet once daily
  • TAK-438 20 mg tablet twice daily All participants will be asked to take TAK-438 tablet at the same time on Day 1 and Days 3-9.

This single-centre trial will be conducted in China. The overall time to participate in this study is 18 days. Participants will remain confined to the clinic from Day 1 up to Day 11 and will be followed-up by telephone or visit on Day 18.

02

Conditions studied

  • Healthy Participants

Keywords

  • Drug Therapy
03

In context

Lead sponsor

Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.

Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Is a healthy adult male or female Chinese participant.
  2. Is aged 18 to 45 years, inclusive, at the time of signing the form.
  3. Weighs at least 50 kilogram (kg) and has a (BMI) between 19 and 26 kilogram per square meter (kg/m\^2), inclusive at Screening (Check-In Day -1).
  4. Is willing to abstain from caffeine and alcohol from 72 hours before first dose (Day 1) until the Follow-up Visit on Day 18.
  5. Is willing to abstain from strenuous exercise from 72 hours before first dose (Day 1) until the Follow-up Visit on Day 18.
  6. Is willing to provide a sample for pharmacogenetic analysis (for cytochrome [CYP2C19] genotyping).

Exclusion criteria

Exclusion Criteria:

  1. Has uncontrolled, cardiovascular disease or other abnormality, which may impact the ability of the participant to participate or potentially confound the study results.
  2. Is lactose intolerant or has a known to any component of the formulation of TAK-438.
  3. Has poor peripheral venous access.
  4. Has donated or lost 400 milliliter (mL) or more of his or her blood volume (including plasmapheresis), or had a transfusion of any blood product within 90 days prior to Day 1; or participant has donated or lost more than 200 mL or more of his or her blood in the last 28 days.
  5. Has a history of symptomatic gastroesophageal reflux disease (GERD), Erosive Esophagitis, duodenal ulcer (DU), gastric ulcer (GU), dyspepsia, Barrett's Esophagus, or Zollinger-Ellison (ZE) syndrome or has current or recent (within 6 months) gastrointestinal disease that would be expected to influence the absorption of drugs.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
33 participants (actual)

Study arms

  • Experimental
    TAK-438 10 milligram (mg) Once Daily

    TAK-438 10 mg, tablets, orally, once daily on Days 1, 3-9. Participants were required to fast for a minimum of 10 hours prior administration of assigned treatment.

    Drug: TAK-438

  • Experimental
    TAK-438 20 mg Once Daily

    TAK-438 20 mg, tablets, orally, once daily on Days 1, 3-9. Participants were asked to fast for a minimum of 10 hours prior administration of assigned treatment.

    Drug: TAK-438

  • Experimental
    TAK-438 20 mg Twice Daily

    TAK-438 20 mg, tablets, orally, once on Day 1 and twice daily on Days 3-9. Participants were asked to fast for a minimum of 10 hours prior to breakfast, followed by administration of assigned treatment 0.5 hours after breakfast and dinner.

    Drug: TAK-438

Interventions

06

What researchers measure

Primary outcomes

  1. Cmax: Maximum Observed Plasma Concentration for Free Base of TAK-438 (TAK-438F) and Its Metabolites M-I, M-II, M-III and M-IV-Sul on Day 1

    Time frame: Day 1 pre-dose and at multiple timepoints (up to 48 hours) post-dose

  2. Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-438F and Its Metabolites M-I, M-II, M-III and M-IV-Sul on Day 1

    Time frame: Day 1 pre-dose and at multiple timepoints (up to 48 hours) post-dose

  3. AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-438F and Its Metabolites M-I, M-II, M-III and M-IV-Sul on Day 1

    Time frame: Day 1 pre-dose and at multiple timepoints (up to 48 hours) post-dose

  4. AUCτ: Area Under the Plasma Concentration-time Curve From Time 0 to Tau Over the Dosing Interval for TAK-438F and Its Metabolites M-I, M-II, M-III and M-IV-Sul on Day 1

    Time frame: Day 1 pre-dose and at multiple timepoints (up to 48 hours) post-dose

  5. T1/2z: Terminal Disposition Half-life for TAK-438F and Its Metabolites M-I, M-II, M-III and M-IV-Sul on Day 1

    Time frame: Day 1 pre-dose and at multiple timepoints (up to 48 hours) post-dose

  6. Cmax,ss: Maximum Observed Plasma Concentration, at Steady State for TAK-438F and Its Metabolites M-I, M-II, M-III and M-IV-Sul on Day 9

    Time frame: Day 9 pre-dose and at multiple timepoints (up to 24 hours for TAK-483 10 mg once daily and 20 mg once daily; up to 12 hours for TAK-438 20 mg twice daily) post-dose

  7. Tmax, ss: Time to Reach the Maximum Plasma Concentration (Cmax) at Steady State for TAK-438F and Its Metabolites M-I, M-II, M-III and M-IV-Sul on Day 9

    Time frame: Day 9 pre-dose and at multiple timepoints (up to 24 hours for TAK-483 10 mg once daily and 20 mg once daily; up to 12 hours for TAK-438 20 mg twice daily) post-dose

  8. AUCτ,ss: Area Under the Plasma Concentration-time Curve During a Dosing Interval, at Steady State for TAK-438F and Its Metabolites M-I, M-II, M-III and M-IV-Sul on Day 9

    Time frame: Day 9 pre-dose and at multiple timepoints (up to 24 hours for TAK-483 10 mg once daily and 20 mg once daily; up to 12 hours for TAK-438 20 mg twice daily) post-dose

  9. Aet: Total Amount of Drug Excreted in Urine From Time 0 to Time T for TAK-438F and Its Metabolites M-I, M-II, M-III and M-IV-Sul on Day 1

    Time frame: Day 1 pre-dose and at multiple timepoints (up to 48 hours) post-dose

  10. Fe,t: Fraction of Drug Excreted in Urine From Time 0 to Time t for TAK-438F and Its Metabolites M-I, M-II, M-III and M-IV-Sul on Day 1

    Time frame: Day 1 pre-dose and at multiple timepoints (up to 48 hours) post-dose

  11. CLr: Renal Clearance for TAK-438F and Its Metabolites M-I, M-II, M-III and M-IV-Sul on Day 1

    Time frame: Day 1 pre-dose and at multiple timepoints (up to 48 hours) post-dose

  12. Aeτ: Amount of Drug Excreted in Urine During a Dosing Interval for TAK-438F and Its Metabolites M-I, M-II, M-III and M-IV-Sul on Day 9

    Time frame: Day 9 pre-dose and at multiple timepoints (up to 24 hours for TAK-483 10 mg once daily and 20 mg once daily; up to 12 hours for TAK-438 20 mg twice daily) post-dose

  13. Fe,τ: Fraction of Administered Dose of Drug Excreted in Urine During a Dosing Interval for TAK-438F and Its Metabolites M-I, M-II, M-III and M-IV-Sul on Day 9

    Time frame: Day 9 pre-dose and at multiple timepoints (up to 24 hours for TAK-483 10 mg once daily and 20 mg once daily; up to 12 hours for TAK-438 20 mg twice daily) post-dose

  14. CLR: Renal Clearance for TAK-438F and Its Metabolites M-I, M-II, M-III and M-IV-Sul on Day 9

    Time frame: Day 9 pre-dose and at multiple timepoints (up to 24 hours for TAK-483 10 mg once daily and 20 mg once daily; up to 12 hours for TAK-438 20 mg twice daily) post-dose

07

Results

Posted Jan 30, 2019

Participant flow

Participants took part in the study at 1 investigative site in China from 19 April 2017 to 17 August 2017.

Participant flow — Overall Study
MilestoneTAK-438 10 mg Once DailyTAK-438 20 mg Once DailyTAK-438 20 mg Twice Daily
Started121110
Completed121110
Not completed000

Outcome measures

PrimaryCmax: Maximum Observed Plasma Concentration for Free Base of TAK-438 (TAK-438F) and Its Metabolites M-I, M-II, M-III and M-IV-Sul on Day 1
Time frame:
Day 1 pre-dose and at multiple timepoints (up to 48 hours) post-dose
Reported as:
Mean · nanogram per milliliter (ng/mL)
Cmax: Maximum Observed Plasma Concentration for Free Base of TAK-438 (TAK-438F) and Its Metabolites M-I, M-II, M-III and M-IV-Sul on Day 1
nanogram per milliliter (ng/mL)TAK-438 10 mg Once DailyTAK-438 20 mg Once DailyTAK-438 20 mg Twice Daily
TAK-438F9.148 ± 2.997218.18 ± 4.497325.23 ± 10.017
M-I38.32 ± 8.614367.95 ± 23.38859.02 ± 18.443
M-II2.840 ± 1.04425.155 ± 2.78684.879 ± 2.2426
M-III15.42 ± 3.778825.63 ± 7.865025.67 ± 5.9219
M-IV-Sul28.29 ± 5.056360.67 ± 16.49942.28 ± 9.1174
PrimaryTmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-438F and Its Metabolites M-I, M-II, M-III and M-IV-Sul on Day 1
Time frame:
Day 1 pre-dose and at multiple timepoints (up to 48 hours) post-dose
Reported as:
Median · hour
Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-438F and Its Metabolites M-I, M-II, M-III and M-IV-Sul on Day 1
hourTAK-438 10 mg Once DailyTAK-438 20 mg Once DailyTAK-438 20 mg Twice Daily
TAK-438F1.750 (1.00 to 4.02)2.000 (0.750 to 4.00)2.500 (0.750 to 4.00)
M-I1.500 (0.750 to 2.00)1.500 (0.750 to 3.00)2.000 (1.00 to 4.00)
M-II4.010 (3.00 to 10.0)6.000 (3.00 to 10.0)10.00 (3.00 to 12.0)
M-III1.750 (1.00 to 2.00)2.000 (1.50 to 3.00)2.000 (1.50 to 4.00)
M-IV-Sul1.500 (1.00 to 2.00)1.500 (1.50 to 3.00)2.000 (1.50 to 3.00)
PrimaryAUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-438F and Its Metabolites M-I, M-II, M-III and M-IV-Sul on Day 1
Time frame:
Day 1 pre-dose and at multiple timepoints (up to 48 hours) post-dose
Reported as:
Mean · hour*nanogram per milliliter (h*ng/mL)
AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-438F and Its Metabolites M-I, M-II, M-III and M-IV-Sul on Day 1
hour*nanogram per milliliter (h*ng/mL)TAK-438 10 mg Once DailyTAK-438 20 mg Once DailyTAK-438 20 mg Twice Daily
TAK-438F84.38 ± 29.197188.1 ± 43.066226.8 ± 67.128
M-I305.7 ± 88.227617.2 ± 213.56578.7 ± 144.15
M-II52.97 ± 22.843106.3 ± 74.306117.8 ± 41.170
M-III92.83 ± 34.769178.7 ± 64.779193.7 ± 56.808
M-IV-Sul132.5 ± 44.602307.5 ± 89.884240.8 ± 82.555
PrimaryAUCτ: Area Under the Plasma Concentration-time Curve From Time 0 to Tau Over the Dosing Interval for TAK-438F and Its Metabolites M-I, M-II, M-III and M-IV-Sul on Day 1
Time frame:
Day 1 pre-dose and at multiple timepoints (up to 48 hours) post-dose
Reported as:
Mean · h*ng/mL
AUCτ: Area Under the Plasma Concentration-time Curve From Time 0 to Tau Over the Dosing Interval for TAK-438F and Its Metabolites M-I, M-II, M-III and M-IV-Sul on Day 1
h*ng/mLTAK-438 10 mg Once DailyTAK-438 20 mg Once DailyTAK-438 20 mg Twice Daily
TAK-438F74.91 ± 24.835168.6 ± 37.455154.8 ± 38.920
M-I251.4 ± 77.758528.8 ± 182.62344.1 ± 91.089
M-II31.77 ± 18.64679.07 ± 56.20641.55 ± 19.189
M-III87.98 ± 31.136169.2 ± 59.474149.1 ± 36.714
M-IV-Sul127.1 ± 43.648296.0 ± 86.359192.8 ± 57.176
PrimaryT1/2z: Terminal Disposition Half-life for TAK-438F and Its Metabolites M-I, M-II, M-III and M-IV-Sul on Day 1
Time frame:
Day 1 pre-dose and at multiple timepoints (up to 48 hours) post-dose
Reported as:
Mean · hour
T1/2z: Terminal Disposition Half-life for TAK-438F and Its Metabolites M-I, M-II, M-III and M-IV-Sul on Day 1
hourTAK-438 10 mg Once DailyTAK-438 20 mg Once DailyTAK-438 20 mg Twice Daily
TAK-438F7.879 ± 1.23526.996 ± 1.01107.116 ± 0.71638
M-I10.82 ± 4.09238.256 ± 1.29648.385 ± 0.73316
M-II10.52 ± 4.331110.37 ± 2.997312.29 ± 4.0538
M-III6.695 ± 1.37866.335 ± 1.18336.791 ± 0.89228
M-IV-Sul4.753 ± 2.44305.698 ± 1.26255.521 ± 2.2225
PrimaryCmax,ss: Maximum Observed Plasma Concentration, at Steady State for TAK-438F and Its Metabolites M-I, M-II, M-III and M-IV-Sul on Day 9
Time frame:
Day 9 pre-dose and at multiple timepoints (up to 24 hours for TAK-483 10 mg once daily and 20 mg once daily; up to 12 hours for TAK-438 20 mg twice daily) post-dose
Reported as:
Mean · ng/mL
Cmax,ss: Maximum Observed Plasma Concentration, at Steady State for TAK-438F and Its Metabolites M-I, M-II, M-III and M-IV-Sul on Day 9
ng/mLTAK-438 10 mg Once DailyTAK-438 20 mg Once DailyTAK-438 20 mg Twice Daily
TAK-438F11.01 ± 3.486323.43 ± 6.143337.88 ± 10.910
M-I43.39 ± 9.652879.85 ± 22.11959.55 ± 15.512
M-II3.558 ± 1.49836.554 ± 2.60789.174 ± 2.8376
M-III16.62 ± 4.191930.15 ± 7.322833.01 ± 6.1638
M-IV-Sul25.33 ± 3.661954.08 ± 13.92739.74 ± 7.1405
PrimaryTmax, ss: Time to Reach the Maximum Plasma Concentration (Cmax) at Steady State for TAK-438F and Its Metabolites M-I, M-II, M-III and M-IV-Sul on Day 9
Time frame:
Day 9 pre-dose and at multiple timepoints (up to 24 hours for TAK-483 10 mg once daily and 20 mg once daily; up to 12 hours for TAK-438 20 mg twice daily) post-dose
Reported as:
Median · hour
Tmax, ss: Time to Reach the Maximum Plasma Concentration (Cmax) at Steady State for TAK-438F and Its Metabolites M-I, M-II, M-III and M-IV-Sul on Day 9
hourTAK-438 10 mg Once DailyTAK-438 20 mg Once DailyTAK-438 20 mg Twice Daily
TAK-438F1.500 (0.750 to 3.02)2.000 (0.750 to 3.00)3.000 (0.750 to 4.00)
M-I1.500 (0.750 to 2.02)1.000 (0.750 to 2.00)2.500 (1.00 to 10.0)
M-II4.000 (3.00 to 6.00)3.000 (3.00 to 10.0)3.500 (0.00 to 10.0)
M-III1.750 (1.00 to 3.00)2.000 (1.50 to 3.00)3.000 (1.50 to 4.00)
M-IV-Sul2.000 (1.00 to 3.00)1.500 (1.50 to 2.00)3.000 (1.50 to 4.00)
PrimaryAUCτ,ss: Area Under the Plasma Concentration-time Curve During a Dosing Interval, at Steady State for TAK-438F and Its Metabolites M-I, M-II, M-III and M-IV-Sul on Day 9
Time frame:
Day 9 pre-dose and at multiple timepoints (up to 24 hours for TAK-483 10 mg once daily and 20 mg once daily; up to 12 hours for TAK-438 20 mg twice daily) post-dose
Reported as:
Mean · h*ng/mL
AUCτ,ss: Area Under the Plasma Concentration-time Curve During a Dosing Interval, at Steady State for TAK-438F and Its Metabolites M-I, M-II, M-III and M-IV-Sul on Day 9
h*ng/mLTAK-438 10 mg Once DailyTAK-438 20 mg Once DailyTAK-438 20 mg Twice Daily
TAK-438F93.90 ± 28.053212.7 ± 57.214273.4 ± 71.830
M-I285.5 ± 77.884581.1 ± 198.14435.3 ± 92.064
M-II46.31 ± 24.298105.5 ± 51.688100.4 ± 27.966
M-III95.94 ± 29.719194.6 ± 53.749222.6 ± 49.670
M-IV-Sul117.1 ± 37.489256.1 ± 62.786225.7 ± 52.675
PrimaryAet: Total Amount of Drug Excreted in Urine From Time 0 to Time T for TAK-438F and Its Metabolites M-I, M-II, M-III and M-IV-Sul on Day 1
Time frame:
Day 1 pre-dose and at multiple timepoints (up to 48 hours) post-dose
Reported as:
Mean · microgram (mcg)
Aet: Total Amount of Drug Excreted in Urine From Time 0 to Time T for TAK-438F and Its Metabolites M-I, M-II, M-III and M-IV-Sul on Day 1
microgram (mcg)TAK-438 10 mg Once DailyTAK-438 20 mg Once DailyTAK-438 20 mg Twice Daily
TAK-438F448.5 ± 159.06890.3 ± 243.241478 ± 405.32
M-I176.6 ± 79.813253.1 ± 118.69211.2 ± 124.21
M-II0.000 ± 0.00000.000 ± 0.00000.000 ± 0.0000
M-III0.000 ± 0.00000.000 ± 0.00000.5120 ± 1.6191
M-IV-Sul205.4 ± 61.587422.1 ± 143.24387.1 ± 142.06
PrimaryFe,t: Fraction of Drug Excreted in Urine From Time 0 to Time t for TAK-438F and Its Metabolites M-I, M-II, M-III and M-IV-Sul on Day 1
Time frame:
Day 1 pre-dose and at multiple timepoints (up to 48 hours) post-dose
Reported as:
Mean · percentage of drug
Fe,t: Fraction of Drug Excreted in Urine From Time 0 to Time t for TAK-438F and Its Metabolites M-I, M-II, M-III and M-IV-Sul on Day 1
percentage of drugTAK-438 10 mg Once DailyTAK-438 20 mg Once DailyTAK-438 20 mg Twice Daily
TAK-438F4.485 ± 1.59064.448 ± 1.20937.399 ± 2.0335
M-I1.760 ± 0.796781.262 ± 0.591221.053 ± 0.61992
M-II0.000 ± 0.00000.000 ± 0.00000.000 ± 0.0000
M-III0.000 ± 0.00000.000 ± 0.00000.002460 ± 0.0077792
M-IV-Sul1.609 ± 0.482581.650 ± 0.561081.513 ± 0.55536
PrimaryCLr: Renal Clearance for TAK-438F and Its Metabolites M-I, M-II, M-III and M-IV-Sul on Day 1
Time frame:
Day 1 pre-dose and at multiple timepoints (up to 48 hours) post-dose
Reported as:
Mean · liter per hour (L/h)
CLr: Renal Clearance for TAK-438F and Its Metabolites M-I, M-II, M-III and M-IV-Sul on Day 1
liter per hour (L/h)TAK-438 10 mg Once DailyTAK-438 20 mg Once DailyTAK-438 20 mg Twice Daily
TAK-438F5.443 ± 1.03984.922 ± 1.43626.733 ± 1.3109
M-I0.6235 ± 0.164370.4465 ± 0.241930.3753 ± 0.19679
M-II0.000 ± 0.00000.000 ± 0.00000.000 ± 0.0000
M-III0.000 ± 0.00000.000 ± 0.00000.001820 ± 0.0057553
M-IV-Sul1.748 ± 0.659481.527 ± 0.774441.707 ± 0.47416
PrimaryAeτ: Amount of Drug Excreted in Urine During a Dosing Interval for TAK-438F and Its Metabolites M-I, M-II, M-III and M-IV-Sul on Day 9
Time frame:
Day 9 pre-dose and at multiple timepoints (up to 24 hours for TAK-483 10 mg once daily and 20 mg once daily; up to 12 hours for TAK-438 20 mg twice daily) post-dose
Reported as:
Mean · mcg
Aeτ: Amount of Drug Excreted in Urine During a Dosing Interval for TAK-438F and Its Metabolites M-I, M-II, M-III and M-IV-Sul on Day 9
mcgTAK-438 10 mg Once DailyTAK-438 20 mg Once DailyTAK-438 20 mg Twice Daily
TAK-438F437.7 ± 121.93859.9 ± 155.661327 ± 274.04
M-I224.3 ± 79.531354.1 ± 165.88340.9 ± 181.71
M-II0.000 ± 0.00000.000 ± 0.00000.000 ± 0.0000
M-III0.000 ± 0.00000.000 ± 0.00000.000 ± 0.0000
M-IV-Sul205.2 ± 52.172390.7 ± 99.477446.4 ± 139.39
PrimaryFe,τ: Fraction of Administered Dose of Drug Excreted in Urine During a Dosing Interval for TAK-438F and Its Metabolites M-I, M-II, M-III and M-IV-Sul on Day 9
Time frame:
Day 9 pre-dose and at multiple timepoints (up to 24 hours for TAK-483 10 mg once daily and 20 mg once daily; up to 12 hours for TAK-438 20 mg twice daily) post-dose
Reported as:
Mean · percentage of drug
Fe,τ: Fraction of Administered Dose of Drug Excreted in Urine During a Dosing Interval for TAK-438F and Its Metabolites M-I, M-II, M-III and M-IV-Sul on Day 9
percentage of drugTAK-438 10 mg Once DailyTAK-438 20 mg Once DailyTAK-438 20 mg Twice Daily
TAK-438F4.377 ± 1.21934.299 ± 0.776786.634 ± 1.3737
M-I2.236 ± 0.793231.765 ± 0.827551.700 ± 0.90664
M-II0.000 ± 0.00000.000 ± 0.00000.000 ± 0.0000
M-III0.000 ± 0.00000.000 ± 0.00000.000 ± 0.0000
M-IV-Sul1.605 ± 0.408531.528 ± 0.389461.748 ± 0.54499
PrimaryCLR: Renal Clearance for TAK-438F and Its Metabolites M-I, M-II, M-III and M-IV-Sul on Day 9
Time frame:
Day 9 pre-dose and at multiple timepoints (up to 24 hours for TAK-483 10 mg once daily and 20 mg once daily; up to 12 hours for TAK-438 20 mg twice daily) post-dose
Reported as:
Mean · L/h
CLR: Renal Clearance for TAK-438F and Its Metabolites M-I, M-II, M-III and M-IV-Sul on Day 9
L/hTAK-438 10 mg Once DailyTAK-438 20 mg Once DailyTAK-438 20 mg Twice Daily
TAK-438F4.848 ± 1.23724.251 ± 1.15654.977 ± 0.71952
M-I0.8126 ± 0.263930.6207 ± 0.226320.7943 ± 0.39001
M-II0.000 ± 0.00000.000 ± 0.00000.000 ± 0.0000
M-III0.000 ± 0.00000.000 ± 0.00000.000 ± 0.0000
M-IV-Sul1.931 ± 0.799071.614 ± 0.586432.067 ± 0.70761

Adverse events

Collected over Treatment-emergent adverse events are adverse events that started after the first dose of study drug up to follow-up (Day 1 up to Day 18). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
TAK-438 10 mg Once Daily0/12 (0%)0/12 (0%)4/12 (33.3%)
TAK-438 20 mg Once Daily0/11 (0%)0/11 (0%)6/11 (54.5%)
TAK-438 20 mg Twice Daily0/10 (0%)0/10 (0%)4/10 (40%)
Most frequent other events
Showing 10 of 13
Most frequent other events
EventTAK-438 10 mg Once DailyTAK-438 20 mg Once DailyTAK-438 20 mg Twice Daily
White blood cells urine positiveInvestigations1/122/112/10
Red blood cells urine positiveInvestigations2/120/112/10
Abdominal pain upperGastrointestinal disorders0/121/111/10
Alanine aminotransferase increasedInvestigations0/120/111/10
Aspartate aminotransferase increasedInvestigations0/120/111/10
Blood creatine phosphokinase increasedInvestigations0/120/111/10
Glucose urine presentInvestigations0/120/111/10
Protein urine presentInvestigations0/120/111/10
Atrioventricular block first degreeCardiac disorders0/121/110/10
Urinary tract infectionInfections and infestations0/121/110/10

Baseline characteristics

The pharmacokinetic (PK) set included all participants who received the study drug, had sufficient plasma/urine concentration data to calculate at least 1 PK parameter, and completed the minimum protocol specified procedures with no significant protocol deviations.

Age, Continuous
Age, Continuous(years)TAK-438 10 mg Once DailyTAK-438 20 mg Once DailyTAK-438 20 mg Twice DailyTotal
Mean25.2 ± 2.9523.9 ± 3.9927.2 ± 4.8325.4 ± 4.04
Sex: Female, Male
Sex: Female, Male(Participants)TAK-438 10 mg Once DailyTAK-438 20 mg Once DailyTAK-438 20 mg Twice DailyTotal
Female65415
Male66618
Race (NIH/OMB)
Race (NIH/OMB)(Participants)TAK-438 10 mg Once DailyTAK-438 20 mg Once DailyTAK-438 20 mg Twice DailyTotal
American Indian or Alaska Native0000
Asian12111033
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White0000
More than one race0000
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(Participants)TAK-438 10 mg Once DailyTAK-438 20 mg Once DailyTAK-438 20 mg Twice DailyTotal
China12111033
Height
Height(centimeter (cm))TAK-438 10 mg Once DailyTAK-438 20 mg Once DailyTAK-438 20 mg Twice DailyTotal
Mean166.35 ± 8.426169.59 ± 7.672164.31 ± 9.377166.81 ± 8.498
Weight
Weight(kilogram (kg))TAK-438 10 mg Once DailyTAK-438 20 mg Once DailyTAK-438 20 mg Twice DailyTotal
Mean62.63 ± 7.60166.05 ± 8.50161.66 ± 6.44963.47 ± 7.597
Body mass index (BMI)
Body mass index (BMI)(kilogram per square meter (kg/m^2))TAK-438 10 mg Once DailyTAK-438 20 mg Once DailyTAK-438 20 mg Twice DailyTotal
Mean22.63 ± 2.08622.89 ± 1.71122.88 ± 2.11022.79 ± 1.918
Smoking classification
Smoking classification(Participants)TAK-438 10 mg Once DailyTAK-438 20 mg Once DailyTAK-438 20 mg Twice DailyTotal
Never smoked12111033

3 further baseline measures are reported on the registry.

08

Study locations

1 site
  • Zhongshan Hospital Fudan University
    Shanghai, 200032, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2017 to primary completion in Aug 2017, 3 months.

Results were first posted in Jan 2019, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 16, 2017
First posted
Mar 21, 2017
StartActual
Apr 19, 2017
Primary completionActual
Aug 17, 2017
CompletionActual
Aug 17, 2017
Results first posted
Jan 30, 2019
Last update
Jan 30, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 30, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03085836
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Mar 21, 2017
Start date
Apr 19, 2017
Primary completion
Aug 17, 2017
Completion
Aug 17, 2017
Results posted
Jan 30, 2019
Last update
Jan 30, 2019

Study contacts

Medical Director
study director · Takeda

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vonoprazan

Start the discussion